IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma
Qin Yazhen1; Lu Jin1; Bao Li1; Zhu Honghu1; Li Jinlan1; Li Lingdi1; Lai Yueyun1; Shi Hongxia1; Wang Yazhe1; Liu Yanrong1; Jiang Bin1; Huang Xiaojun1,2
关键词multiple myeloma preferentially expressed antigen of melanoma expression bortezomib progression-free survival real-time quantitative polymerase chain reaction
刊名CHINESE MEDICAL JOURNAL
2014-05-05
DOI10.3760/cma.j.issn.0366-6999.20132356
127期:9页:1666-1671
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]STEM-CELL TRANSPLANTATION ; MINIMAL RESIDUAL DISEASE ; REFRACTORY MYELOMA ; PROGNOSTIC-FACTORS ; LEUKEMIA PATIENTS ; PRAME EXPRESSION ; STAGING SYSTEM ; MANAGEMENT ; PATTERNS ; THERAPY
英文摘要

Background Significant efforts have been made to identify factors that differentiate patients treated with novel therapies, such as bortezomib in multiple myeloma (MM). The exact expression pattern and prognostic value of the cancer/testis antigen preferentially expressed antigen of melanoma (PRAME) in MM are unknown and were explored in this study.

Methods The transcript level of FRAME was detected in bone marrow specimens from 100 newly diagnosed MM patients using real-time quantitative polymerase chain reaction, and the prognostic value of FRAME was determined through retrospective survival analysis. FRAME expression higher than the upper limit of normal bone marrow was defined as PRAME overexpression or FRAME (+).

Results Sixty-two patients (62.0%) overexpressed FRAME. FRAME overexpression showed no prognostic significance to either overall survival (n=100) or progression-free survival (PFS, n=96, all P > 0.05) of patients. The patients were also categorized according to regimens with or without bortezomib. FRAME overexpression tended to be associated with a lower two-year PFS rate in patients treated with non-bortezomib-containing regimens (53.5% vs. 76.9%, P=0.071). By contrast, it was not associated with the two-year PFS rate in patients with bortezomib-containing regimens (77.5% vs. 63.9%, P > 0.05). When the patients were categorized into PRAME (+) and FRAME () groups, treatment with bortezomib-containing regimens predicted a higher two-year PFS rate in FRAME (+) patients (77.5% vs. 53.5%, P=0.027) but showed no significant effect on two-year PFS rate in FRAME () patients (63.9% vs. 76.9%, P > 0.05).

Conclusion FRAME overexpression might be an adverse prognostic factor of PFS in MM patients treated with non-bortezonnib-containing regimens. Bortezomib improves PFS in patients overexpressing PRAME.

语种英语
WOS记录号WOS:000335936800012
项目编号Z111107067311070 ; 81170483 ; 81372535
资助机构Beijing Municipal Science and Technology Program ; Nature Science Foundation of China
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/68197
专题北京大学第二临床医学院_血液科
北京大学药学院_药事管理与临床药学系
作者单位1.Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
2.Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Qin Yazhen,Lu Jin,Bao Li,et al. Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma[J]. CHINESE MEDICAL JOURNAL,2014,127(9):1666-1671.
APA Qin Yazhen.,Lu Jin.,Bao Li.,Zhu Honghu.,Li Jinlan.,...&Huang Xiaojun.(2014).Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma.CHINESE MEDICAL JOURNAL,127(9),1666-1671.
MLA Qin Yazhen,et al."Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma".CHINESE MEDICAL JOURNAL 127.9(2014):1666-1671.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Qin Yazhen]的文章
[Lu Jin]的文章
[Bao Li]的文章
百度学术
百度学术中相似的文章
[Qin Yazhen]的文章
[Lu Jin]的文章
[Bao Li]的文章
必应学术
必应学术中相似的文章
[Qin Yazhen]的文章
[Lu Jin]的文章
[Bao Li]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。